Society guideline links: Systemic lupus erythematosus

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Cutaneous lupus erythematosus".)

International

●Kidney Disease: Improving Global Outcomes (KDIGO): Clinical practice guideline for the management of glomerular diseases (2021)

●International consensus for the dosing of corticosteroids in childhood-onset systemic lupus erythematosus with proliferative lupus nephritis (2021)

●Treat-to-target in systemic lupus erythematosus – Recommendations from an international task force (2014)

Canada

●Choosing Wisely Canada: Don't order ANA as a screening test in patients without specific signs or symptoms of systemic lupus erythematosus (SLE) or another connective tissue disease (CTD) (2022)

●Canadian Rheumatology Association (CRA): Recommendations for the assessment and monitoring of systemic lupus erythematosus (2018)

United States

●American College of Rheumatology (ACR): Guideline for the management of reproductive health in rheumatic and musculoskeletal diseases (2020)

●European League Against Rheumatism (EULAR)/ACR: Classification criteria for systemic lupus erythematosus (2019)

●Childhood Arthritis and Rheumatology Research Alliance (CARRA): Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus (2012)

Latin America

●Latin American Group for the Study of Lupus (GLADEL)-Pan-American League of Associations of Rheumatology (PANLAR): First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus (2018)

Europe

●European League Against Rheumatism (EULAR): Recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis (2023)

●EULAR/Pediatric Rheumatology European Society (PReS): Recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases, 2021 update (published 2023)

●EULAR: Recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome (2022)

●EULAR and European Renal Association-European Dialysis and Transplant Association (ERA-EDTA): Joint recommendations for the management of lupus nephritis, 2019 update (published 2020)

●EULAR: Recommendations for the management of systemic lupus erythematosus, update (2019)

●EULAR: Recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, update (2019)

●EULAR/American College of Rheumatology (ACR): Classification criteria for systemic lupus erythematosus (2019)

●EULAR: Recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome (2017)

●Single Hub and Access point for paediatric Rheumatology in Europe (SHARE): European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis (2017)

●SHARE: European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus (2017)

●EULAR: Recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies (2010)

United Kingdom

●British Society for Rheumatology (BSR): Guideline for the management of systemic lupus erythematosus in adults (2018)

●Choosing Wisely UK: British Society of Rheumatology – Testing ANA and ENAs should be reserved for patients suspected to have a diagnosis of a connective tissue disease, e.g. lupus. Testing ANA and ENAs should be avoided in the investigation of widespread pain or fatigue alone. Repeat testing is not normally indicated unless the clinical picture changes significantly (2018)

Australia–New Zealand

●Choosing Wisely Australia: Do not order anti-double stranded (ds) DNA antibodies in ANA negative patients unless clinical suspicion of systemic lupus erythematosus (SLE) remains high (2018)